Mariner LLC Purchases 268,570 Shares of Haleon plc (NYSE:HLN)

Mariner LLC grew its position in Haleon plc (NYSE:HLN) by 62.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 695,406 shares of the company’s stock after purchasing an additional 268,570 shares during the quarter. Mariner LLC’s holdings in Haleon were worth $6,634,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Addison Advisors LLC lifted its stake in Haleon by 28.7% in the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock valued at $47,000 after buying an additional 1,106 shares during the period. Synovus Financial Corp lifted its position in shares of Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock valued at $1,575,000 after acquiring an additional 1,216 shares during the period. Haverford Trust Co boosted its stake in Haleon by 5.0% during the fourth quarter. Haverford Trust Co now owns 25,842 shares of the company’s stock worth $247,000 after acquiring an additional 1,233 shares in the last quarter. Bessemer Group Inc. grew its holdings in Haleon by 5.9% in the fourth quarter. Bessemer Group Inc. now owns 22,301 shares of the company’s stock worth $212,000 after purchasing an additional 1,236 shares during the period. Finally, FIL Ltd increased its stake in Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company’s stock valued at $39,000 after purchasing an additional 1,270 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

Shares of Haleon stock opened at $10.22 on Friday. The company has a market cap of $46.16 billion, a PE ratio of 30.06, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 52 week low of $8.12 and a 52 week high of $10.80. The business has a 50 day moving average price of $10.09 and a 200-day moving average price of $9.80.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Equities analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. Haleon’s payout ratio is 58.97%.

Analysts Set New Price Targets

HLN has been the topic of a number of research analyst reports. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Finally, HSBC restated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.